Core Viewpoint - The article highlights the recent funding and technological advancements of Shanghai Ruisi Health Technology Co., Ltd. (Ruisi Technology), focusing on its innovative solutions for myopia prevention and control among children and adolescents [2][4][6]. Company Overview - Ruisi Technology, established in 2017, specializes in myopia prevention for children and adolescents, utilizing AI-driven technologies that integrate artificial intelligence, optical engineering, and neuroscience [6]. - The company has developed proprietary technologies, including AI light-eye-brain neural regulation, and holds multiple intellectual properties, including 84 trademarks and 58 patents [6]. Recent Financing - On June 30, 2025, Ruisi Technology completed a multi-million A2 round of financing, led by Jinke Jun Chuang, with funds allocated for product development, medical device registration, and market expansion [2][11]. - Previous financing rounds include a 50 million RMB A round in December 2022 and a billion-level A+ round in March 2024, aimed at advancing clinical trials for myopia prevention products [11]. Product and Technology - Ruisi Technology's core products include the Vision Training Instrument D1 and MAX 2.0, which utilize advanced algorithms for real-time focus adjustment based on user needs [6][7]. - The company's far-view light screen product is a pioneering intelligent terminal for myopia prevention, employing digital defocus and AR technology [6][7]. Clinical Validation - Clinical studies have shown that Ruisi Technology's far-view light defocus digital technology significantly slows myopia progression, with a 50% reduction in eye axis elongation and an 80% decrease in myopia degree in trial groups [8]. - The company has established its products in over 400 cities across China and has partnered with over 600 professional institutions [8]. Industry Standards - Ruisi Technology has played a key role in setting industry standards, collaborating with Wenzhou Medical University to publish technical specifications for far-view electronic display terminals in June 2025 [8].

Core Viewpoint - Ambu's aScope 5 Cysto HD has received FDA approval for use in percutaneous nephrolithotomy (PCNL), marking a significant advancement in the application of disposable endoscopes in complex urological surgeries, enhancing the platform's capabilities in minimally invasive procedures [2][15]. Product Development and Features - The aScope 5 Cysto HD is a high-resolution, bidirectional flexible endoscope designed initially for bladder examinations and ureteral observations, now expanded to include kidney stone surgeries [3][14]. - The endoscope has a diameter between 4.8 to 5.4 mm, with a tip deflection of up to 210°, and features a CMOS image sensor supporting 1080p HD imaging, providing superior visualization in complex anatomical areas [5][15]. - The single-use nature of the aScope 5 Cysto HD significantly reduces the risk of cross-contamination and simplifies the preparation and cleaning processes compared to traditional reusable endoscopes [5][15]. Clinical Application and Advantages - In PCNL procedures, the aScope 5 Cysto HD can assist in stone localization, enhance stone fragmentation efficiency, and confirm the absence of residual stones post-surgery [10][11]. - The system supports dual visualization by integrating with Ambu's aScope 5 Uretero, allowing simultaneous display and control of two endoscopes, which saves time and reduces anesthesia exposure during surgery [9][10]. Market Position and Strategy - Ambu holds over 50% market share in the global disposable endoscope market, with its aScope series utilized in over 8,000 medical institutions [12]. - The company’s strategy focuses on a "procedure-oriented + platform synergy" approach, differentiating itself from traditional reusable endoscope manufacturers [12][16]. Future Outlook - Ambu plans to initiate larger-scale clinical trials in 2026 to further validate the aScope 5 Cysto HD's adaptability and long-term efficacy across various patient demographics and surgical complexities [13]. - The company is also exploring the expansion of its aScope platform into gastroenterology and respiratory fields, aiming for multidisciplinary collaboration and integration of advanced features like 4K imaging and AI navigation [13][16].

Core Viewpoint - Carlsmed is seeking to go public with an IPO on NASDAQ under the ticker "CARL," driven by advancements in AI-driven personalized spinal fusion solutions and a resurgence in the medical technology sector [1] Group 1: Company Overview - Carlsmed focuses on complex adult spinal deformities, offering the aprevo® platform, which integrates AI-driven modeling, custom device manufacturing, and postoperative data feedback into a comprehensive surgical system [3] - The company has raised over $80 million in funding over the past two years, establishing industry barriers in capital, technology, and team [18] Group 2: Technology and Innovation - The aprevo® platform utilizes patient CT scan data to create individualized 3D spinal models and correction paths, allowing surgeons to review and modify surgical plans online [5] - Each aprevo® fusion device is custom-designed based on the patient's anatomy, reducing common issues related to device mismatch and postoperative complications [7] - The fusion devices are produced using 3D printing technology, pre-setting alignment angles and correction directions to enhance surgical precision [8] Group 3: Postoperative Tracking and Outcomes - Postoperative data is analyzed by the aprevo® platform to compare pre-surgical designs with actual outcomes, providing insights for further optimization [10] - Initial results from a two-year prospective study involving over 300 patients show a 94% endplate contact rate and a 96% absence of collapse, with 82% of segments achieving alignment within ±5° of the target [12][13] Group 4: Market Potential and Challenges - The adult spinal deformity market has significant unmet needs, with conditions affecting quality of life more severely than arthritis, COPD, and diabetes [19] - Despite the potential, challenges remain in the commercialization of personalized devices, including production cycles, surgical team training, and insurance coverage [19]

Core Viewpoint - Mindray Medical aims to become one of the top ten or even top five medical device companies globally, leveraging its strong competitive position in the Chinese market, particularly in the monitoring equipment sector [4]. Group 1: Investor Relations Activities - Mindray Medical conducted a series of investor relations activities from May 19 to June 27, 2025, attracting 382 institutions and 713 investors [3]. Group 2: Competitive Advantages - The company's success is attributed to its meticulous attention to detail and solid execution across R&D, management, and sales, alongside a strong focus on employee training and welfare [5]. Group 3: Addressing Performance Challenges - Mindray identified reasons for slowing growth, including post-pandemic demand decline and trade friction, and is focusing on high-end market needs and overseas expansion to regain rapid growth [6]. Group 4: Domestic Policy Adaptation - The company views centralized procurement policies as a necessary step towards market maturity in China, which ultimately presents opportunities for leading domestic firms [7]. Group 5: International Strategy - Mindray aims for international revenue to account for 70% of its total, with over 60 overseas subsidiaries and a focus on local production and compliance with international regulations [8]. Group 6: Business Transformation - The company is preparing for a transformation in its business model by acquiring Huatai to enhance its core technology and expand into high-value consumables [9]. Group 7: Product Development and Market Position - Mindray is narrowing the gap with Roche in the chemiluminescence sector through strategic acquisitions and local production, with confidence in competing with imported brands [10]. Group 8: Data Integration and Device Advantage - The "Ruizhi Lian" data platform integrates with most mainstream devices, providing comprehensive and accurate patient data, which is a significant competitive edge [12]. Group 9: R&D Resource Allocation - The company balances R&D resources to support both core and emerging businesses, ensuring stability in main operations while fostering new growth areas [13]. Group 10: Personalized Product Development - Mindray conducts market research in target countries during product development, ensuring that products meet local clinical needs before full market launch [14]. Group 11: IVD Product Line Improvements - Mindray's MT8000 product line addresses inefficiencies found in imported brands, with ongoing efforts to enhance functionality and adapt to European market needs [15]. Group 12: MPI System Adaptation - The company is refining its MPI system to better suit the needs of its IT and consumable businesses, ensuring rapid iteration and effective project execution [16]. Group 13: Growth Challenges and Strategies - Mindray recognizes its limitations in marketing and local delivery for high-value consumables and is considering both internal development and acquisitions to address these gaps [18]. Group 14: "Sanrui" Ecosystem Strategy - The "Sanrui" ecosystem model is designed to integrate clinical data and enhance automation and intelligence in medical devices, with plans for local deployment and information security [19]. Group 15: Innovation in Product Development - Mindray emphasizes technical innovation, focusing on user needs and product performance, as demonstrated by the successful launch of its ultrasound knife [20]. Group 16: Company Overview - Founded in 1991, Mindray Medical is China's largest medical device manufacturer, with a global presence and a strong R&D team [21]. Group 17: Financial Performance - In 2024, Mindray reported a revenue of 36.73 billion, a 5.1% increase year-on-year, with a net profit of 11.67 billion, reflecting a 0.7% growth [22].

Core Viewpoint - The medical robotics industry has entered a complex phase by 2025, with evolving product forms, clearer clinical pathways, and a more rational capital environment, emphasizing the need for a comprehensive ecosystem [1] Group 1: Event Overview - The Third Global Surgical Robotics Conference will take place from September 4-6, 2025, in Beijing, focusing on the theme "MedRobot Next: The Future of Technology" [2] - The conference serves as a platform for discussing technological advancements, supply chain transformations, hospital system upgrades, and international trends [1][2] Group 2: Key Themes - The conference will cover topics such as the systematic upgrade of intelligent surgical systems, the construction of a full-chain ecosystem, and global pathways for development [1] - It aims to redefine how hospitals will be reconstructed through robotics, moving beyond just equipment discussions [1][12] Group 3: Industry Insights - The event will feature the launch of the "Global Surgical Robotics Industry Report 2025" and an annual industry awards ceremony [3] - Discussions will include the integration of clinical needs into engineering goals, the evolution of surgical robots across various specialties, and the challenges of integrating robotic systems into hospital frameworks [7][13] Group 4: Commercialization and Global Strategy - The conference will explore commercialization paths for surgical robots, comparing global market experiences and identifying real demands in different regions such as Europe, Southeast Asia, and the Middle East [8] - It will also address the financing challenges faced by surgical robotics and strategies for overcoming these hurdles [8] Group 5: Supply Chain and Ecosystem - The importance of building a complete medical robotics industry chain and the role of domestic core components will be discussed, highlighting opportunities and bottlenecks [13] - The conference will emphasize the need for standardized technology and collaborative mechanisms within the supply chain [13]

Core Viewpoint - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [1]. Training Information - The workshop titled "Medical Device Innovation and Engineering Transformation Workshop" aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [5]. - The workshop will take place on August 16-17, 2025, at Shanghai Jiao Tong University School of Medicine, with a fee of 8999 yuan per person, covering course materials and refreshments [10]. Course Highlights - Participants will learn the Biodesign innovation methodology, which is a global leading model for medical engineering innovation, focusing on efficient transformation [6]. - The course includes practical training on identifying medical needs, generating creative solutions, and understanding the complete path from concept to market for medical devices [11][12]. - Networking opportunities will be provided to connect with doctors, researchers, industry experts, and investors, enhancing professional development [6]. Course Structure - The first day will cover medical innovation and technology layout, followed by practical innovation exercises and team drills to foster interdisciplinary collaboration [7][9]. - The second day will focus on the industrialization of innovation and team building, including discussions on funding sources and investment opportunities in the medical engineering sector [13][16]. Expert Faculty - The workshop features a team of distinguished faculty members from Shanghai Jiao Tong University, including experts in biomedical engineering and medical technology innovation, who bring extensive experience in research and industry [14][17].

Core Viewpoint - The second Global Medical Technology Conference will be held on July 17, 2025, in Beijing, focusing on "Cutting-edge Technology: From R&D to Clinical Application" [1][6]. Group 1: Conference Overview - The conference will take place at the Zhongguancun Exhibition Center in Haidian District, Beijing [6]. - The expected attendance is approximately 500 participants, including representatives from government, hospitals, leading enterprises, startups, investment institutions, and research institutes [8]. - The agenda will include discussions on product innovation, technology implementation, and medical-engineering collaboration [6][8]. Group 2: Key Topics of Discussion - The conference will explore challenges in the implementation of medical AI and large models, including multi-modal data integration and embedding solutions into doctors' workflows [9]. - Topics will also cover advancements in imaging equipment and platform upgrades, high-value consumables, energy systems, and material innovations [10][11][12][13]. - A roundtable discussion will focus on how innovative products can effectively enter clinical settings and be utilized [14]. Group 3: Awards and Recognition - The conference will feature a significant awards ceremony to showcase and honor global medical technology innovations [8]. Group 4: Registration Information - Interested parties can register via a provided link or by scanning a QR code [15].

思宇去年评选了两次 2024 年全球医疗科技新锐奖 与 2024 年全球医疗技术创新奖 ， 24年上半年纳入榜单的企业在6月28号已参加了颁奖典礼。 现欢迎24年年底补录的企业参加7月17号的2025的颁奖典礼，补领奖项。 名单附后，企业如果参加的话请 填写文末信息收集表 ， 注：如果不参与则视为放弃，我们不再进行补发。 # 获奖企业信息收集： 获奖企业请复制以下链接到IE浏览器进行填写 https://docs.qq.com/form/page/DUGVhbUdJeGNnVFNy 如有不明，可以咨询。 工作微信号： suribot22 手机号： 13552754250 也可以直接联系主编赵清、Alice、Jacky、Ziana 等任何思宇团队的工作人员 欢迎企业积极参与思宇组织的大会↓ 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 纯免费哈，我们准备奖牌，但是企业需要自行负担差旅。 | | 思宇MedTech MedRobot 眼未来 心未来 骨未来 医影像 | | --- | --- | | 2024全球医疗技术创新奖 中国获奖企业名单 | | | 迈瑞医 ...

Core Viewpoint - The article emphasizes the importance of cultivating entrepreneurial thinking in the medical industry to navigate complex challenges and unlock future opportunities in healthcare [7][14]. Group 1: Educational Programs and Methodologies - The Shanghai Jiao Tong University School of Medicine offers a unique educational program that integrates academic research, clinical practice, and industry application, aiming to develop leaders in the medical field [9][10]. - The "Value Engine Methodology" is introduced, focusing on collaborative efforts between academia and industry to foster strategic vision, innovation capabilities, and leadership skills among participants [10][15]. - The curriculum includes modules on industry insights, strategic execution, and innovative thinking, addressing the evolving landscape of the healthcare sector [18][19]. Group 2: Industry Trends and Challenges - The program addresses current trends and challenges in the medical industry, including the impact of macroeconomic factors and the need for strategic adaptation in a rapidly changing environment [13][18]. - It highlights the significance of understanding the "silver economy" and its associated opportunities and challenges, particularly in sectors like elderly care and healthcare innovation [19]. Group 3: Networking and Resource Integration - The initiative facilitates connections between entrepreneurs and scientists through various events, including annual conferences and international study tours, to enhance collaboration and resource sharing [22][23]. - The program aims to build a top-tier resource platform for the healthcare industry, connecting participants with leading institutions and companies globally [24][25].

Core Insights - The article highlights the upcoming global medical technology conferences and recent approvals of innovative medical devices in China, emphasizing the growth and innovation in the medical technology sector [1][13]. Group 1: Medical Device Approvals - On June 27, 2025, three innovative medical devices received approval from the National Medical Products Administration of China, including a spinal surgery navigation device, a cardiac pulsed electric field ablation device, and a biodegradable magnesium alloy screw [1][2]. - As of now, a total of 360 innovative medical devices have been approved for market in China [1]. Group 2: Spinal Surgery Navigation Device - The spinal surgery navigation device from China-Europe Zhihui (Shanghai) Robot Co., Ltd. is the first in China to utilize micro robotic arm technology, allowing for precise spatial positioning during adult spinal surgeries [3]. - This device significantly reduces the space occupied in the operating room compared to traditional multi-axis robotic arms, enhancing safety and efficiency [3]. Group 3: Cardiac Pulsed Electric Field Ablation Device - The cardiac pulsed electric field ablation device from Shenzhen Maiwei Medical Technology Co., Ltd. is designed for treating drug-resistant, recurrent, symptomatic, and paroxysmal atrial fibrillation [8]. - It is the first device to use nanosecond pulse width high-voltage electric fields for pulmonary vein isolation, providing real-time monitoring and feedback during the ablation process [8]. Group 4: Biodegradable Magnesium Alloy Screw - The biodegradable magnesium alloy screw from Syntellix AG is made from a magnesium-based alloy and is designed to gradually degrade and be replaced by endogenous new tissue within the body [11][12]. - Compared to traditional titanium or steel implants, this product claims to reduce surgical time, costs, pain, and infection risks by half [12].